HSBI,
from patents to products

Innovating is safe

Since 2014, Patrick Lamas has applied Reasearch & Development with focused Biotech innovation-oriented profile. SAS HSBI company was founded with €125,000 capital, and operates on its own funds.

In 2017, several patents are already owned by the company’s asset, some other are being obtained.

In addition to gasometry (the historical research area for Patrick Lamas), HSBI expands new R&D axes, empowered by two patents, which are: study of devices against infectious diseases risk with coronary angiography, peripheral catheters placement and arteriovenous fistulas procedures.

Gasometry:
hand to hand…

Each arterial sampling required for gasometry is a potential percutaneous AEB taken risk.
In accordance with the both reports: AES RAISIN 2015 and CCLIN Est 2015, some telling outcomes can be put forward: percutaneous AEBs represent more than 78% of all AEBs, the remaining AEBs are from eye projections, or projections on the face, or on a damaged skin.
Furthermore, among the percutaneous AEBs, 35% occur during sampling.

These blood exposure accidents harm 60% of the paramedical staff, ie more than 8 700 in 14 624 reported accidents. As the mainly concerned staff is less than 5 years seniority (72% CCLIN Est), it can be assumed that they are still being trained.

The CCLIN EST report states that among all the AEBs which could be avoided, 39% concern handling needle.

By conceiving CERTEX, a Hemostatic compressive prophylactic dressing, HSBI offers the best support for healthcare workers by providing them an innovative protection in their hospital practice.

Today, Certex is a conceptually finished-product, already tested in user phase. A prototype is being refined before the clinical trial.

CERTEX by HSBI, close protection in hospitals

14600-2

In 2015, the number of AEBs reported in France was around 15 000, distributed over 825 healthcares facilities. AES-RAISIN Report 2015